◎ Sugi Atlas

Atlas / Drug / Pegozafermin

Pegozafermin

drug
On this page

Also known as BIO89100PegozaferminaPegozafermineTEV-47948

Summary

Pegozafermin (CHEMBL4594466) is a phase-3 clinical-stage protein targeting FGFR1; indicated across 3 conditions including hypertriglyceridemia and metabolic dysfunction-associated steatohepatitis.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Protein
  • Targets: 1 (FGFR1)
  • Indications: 3 conditions
  • Clinical trials: 7

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL4594466
NamePegozafermin
TypeProtein
Max phase3

Also known as: BIO89100, Pegozafermin, Pegozafermina, Pegozafermine, TEV-47948, PEGOZAFERMIN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
FGFR1fibroblast growth factor receptor 1Agonist9.2211.5%P11362

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): FGFR1.

Top Reactome pathways

22 total, by targets touching each:

PathwayTargetsGenes
PI3K Cascade1FGFR1
PIP3 activates AKT signaling1FGFR1
Signaling by FGFR1 amplification mutants1FGFR1
Signaling by activated point mutants of FGFR11FGFR1
FGFR1b ligand binding and activation1FGFR1
FGFR1c ligand binding and activation1FGFR1
FGFR1c and Klotho ligand binding and activation1FGFR1
Constitutive Signaling by Aberrant PI3K in Cancer1FGFR1
NCAM signaling for neurite out-growth1FGFR1
Signal transduction by L11FGFR1
Phospholipase C-mediated cascade: FGFR11FGFR1
Downstream signaling of activated FGFR11FGFR1
SHC-mediated cascade:FGFR11FGFR1
PI-3K cascade:FGFR11FGFR1
FRS-mediated FGFR1 signaling1FGFR1
Negative regulation of FGFR1 signaling1FGFR1
Signaling by FGFR1 in disease1FGFR1
RAF/MAP kinase cascade1FGFR1
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling1FGFR1
Signaling by plasma membrane FGFR1 fusions1FGFR1
Epithelial-Mesenchymal Transition (EMT) during gastrulation1FGFR1
Formation of paraxial mesoderm1FGFR1

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II1
MAPK cascade1
skeletal system development1
angiogenesis1
ureteric bud development1
in utero embryonic development1
organ induction1
neuron migration1
epithelial to mesenchymal transition1
positive regulation of mesenchymal cell proliferation1
chondrocyte differentiation1
protein phosphorylation1
sensory perception of sound1
positive regulation of cell population proliferation1
fibroblast growth factor receptor signaling pathway1

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
hypertriglyceridemia3MONDO:0005347EFO:0004211
metabolic dysfunction-associated steatohepatitis2MONDO:0007027EFO:1001249
metabolic dysfunction-associated steatotic liver disease2MONDO:0013209EFO:0003095

Clinical trials

Total trials: 7.

Phase distribution

PhaseTrials
PHASE33
PHASE22
PHASE1/PHASE21
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05852431PHASE3ACTIVE_NOT_RECRUITINGTo Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
NCT06318169PHASE3RECRUITINGA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06419374PHASE3RECRUITINGA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT04048135PHASE1/PHASE2COMPLETEDA Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
NCT04541186PHASE2COMPLETEDStudy to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
NCT04929483PHASE2COMPLETEDStudy Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
NCT05022693PHASE1COMPLETEDPK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

84 molecules share ≥1 primary target. Top 84 by shared-target count:

MoleculeSourceStatusShared targets
PAZOPANIBChEMBL + PubChemPhase 4 (approved)FGFR1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)FGFR1
AXITINIBChEMBLPhase 4 (approved)FGFR1
BRIGATINIBChEMBLPhase 4 (approved)FGFR1
CABOZANTINIBChEMBLPhase 4 (approved)FGFR1
CAPIVASERTIBChEMBLPhase 4 (approved)FGFR1
DASATINIBChEMBLPhase 4 (approved)FGFR1
ENTRECTINIBChEMBLPhase 4 (approved)FGFR1
ERDAFITINIBChEMBLPhase 4 (approved)FGFR1
FEDRATINIBChEMBLPhase 4 (approved)FGFR1
FUTIBATINIBChEMBLPhase 4 (approved)FGFR1
INFIGRATINIBChEMBLPhase 4 (approved)FGFR1
LENVATINIBChEMBLPhase 4 (approved)FGFR1
MIDOSTAURINChEMBLPhase 4 (approved)FGFR1
NICLOSAMIDEChEMBLPhase 4 (approved)FGFR1
NINTEDANIBChEMBLPhase 4 (approved)FGFR1
NINTEDANIB ESYLATEChEMBLPhase 4 (approved)FGFR1
PEMIGATINIBChEMBLPhase 4 (approved)FGFR1
PONATINIBChEMBLPhase 4 (approved)FGFR1
SORAFENIBChEMBLPhase 4 (approved)FGFR1
SUNITINIBChEMBLPhase 4 (approved)FGFR1
TIVOZANIBChEMBLPhase 4 (approved)FGFR1
UPADACITINIBChEMBLPhase 4 (approved)FGFR1
VANDETANIBChEMBLPhase 4 (approved)FGFR1
ADEFOVIRChEMBLPhase 3FGFR1
ALISERTIBChEMBLPhase 3FGFR1
BRIVANIBChEMBLPhase 3FGFR1
BRIVANIB ALANINATEChEMBLPhase 3FGFR1
CEDIRANIBChEMBLPhase 3FGFR1
DOVITINIBChEMBLPhase 3FGFR1
ENZASTAURINChEMBLPhase 3FGFR1
LESTAURTINIBChEMBLPhase 3FGFR1
LINIFANIBChEMBLPhase 3FGFR1
MOTESANIBChEMBLPhase 3FGFR1
OLVEREMBATINIBChEMBLPhase 3FGFR1
ORANTINIBChEMBLPhase 3FGFR1
RUBOXISTAURINChEMBLPhase 3FGFR1
SEMAXANIBChEMBLPhase 3FGFR1
SURUFATINIBChEMBLPhase 3FGFR1
AG-13958ChEMBLPhase 2FGFR1
AT-9283ChEMBLPhase 2FGFR1
AZD-1480ChEMBLPhase 2FGFR1
BMS-754807ChEMBLPhase 2FGFR1
CENISERTIBChEMBLPhase 2FGFR1
CEP-11981ChEMBLPhase 2FGFR1
DANUSERTIBChEMBLPhase 2FGFR1
DERAZANTINIBChEMBLPhase 2FGFR1
DORAMAPIMODChEMBLPhase 2FGFR1
E-7090ChEMBLPhase 2FGFR1
ENMD-2076ChEMBLPhase 2FGFR1
FEXAGRATINIBChEMBLPhase 2FGFR1
FGFR INHIBITOR DEBIO 1347ChEMBLPhase 2FGFR1
FISOGATINIBChEMBLPhase 2FGFR1
FORETINIBChEMBLPhase 2FGFR1
ILORASERTIBChEMBLPhase 2FGFR1
LIRAFUGRATINIBChEMBLPhase 2FGFR1
LUCITANIBChEMBLPhase 2FGFR1
MILCICLIBChEMBLPhase 2FGFR1
MK-2461ChEMBLPhase 2FGFR1
NARAZACICLIBChEMBLPhase 2FGFR1
OCIFISERTIBChEMBLPhase 2FGFR1
OSI-632ChEMBLPhase 2FGFR1
PEXMETINIBChEMBLPhase 2FGFR1
R-406ChEMBLPhase 2FGFR1
RAF-265ChEMBLPhase 2FGFR1
REBASTINIBChEMBLPhase 2FGFR1
RESIGRATINIBChEMBLPhase 2FGFR1
ROGARATINIBChEMBLPhase 2FGFR1
RX-518ChEMBLPhase 2FGFR1
SEGIGRATINIBChEMBLPhase 2FGFR1
SU-014813ChEMBLPhase 2FGFR1
TANDUTINIBChEMBLPhase 2FGFR1
TOCERANIBChEMBLPhase 2FGFR1
TOZASERTIBChEMBLPhase 2FGFR1
AfatinibPubChemApprovedFGFR1
belumosudilPubChemApprovedFGFR1
BinimetinibPubChemApprovedFGFR1
CrizotinibPubChemApprovedFGFR1
dacomitinibPubChemApprovedFGFR1
FostamatinibPubChemApprovedFGFR1
GefitinibPubChemApprovedFGFR1
IdelalisibPubChemApprovedFGFR1
SelumetinibPubChemApprovedFGFR1
TrametinibPubChemApprovedFGFR1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 29

This page pulls from 29 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot